Annual EBITDA
$126.45 M
+$171.10 M+383.24%
December 31, 2023
Summary
- As of February 7, 2025, VYGR annual EBITDA is $126.45 million, with the most recent change of +$171.10 million (+383.24%) on December 31, 2023.
- During the last 3 years, VYGR annual EBITDA has risen by +$95.25 million (+305.29%).
- VYGR annual EBITDA is now at all-time high.
Performance
VYGR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$12.65 M
+$985.00 K+7.23%
September 30, 2024
Summary
- As of February 7, 2025, VYGR quarterly EBITDA is -$12.65 million, with the most recent change of +$985.00 thousand (+7.23%) on September 30, 2024.
- Over the past year, VYGR quarterly EBITDA has dropped by -$68.05 million (-122.83%).
- VYGR quarterly EBITDA is now -110.20% below its all-time high of $123.96 million, reached on March 31, 2023.
Performance
VYGR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$14.13 M
+$15.91 M+892.04%
September 30, 2024
Summary
- As of February 7, 2025, VYGR TTM EBITDA is $14.13 million, with the most recent change of +$15.91 million (+892.04%) on September 30, 2024.
- Over the past year, VYGR TTM EBITDA has dropped by -$112.33 million (-88.83%).
- VYGR TTM EBITDA is now -88.83% below its all-time high of $126.45 million, reached on December 31, 2023.
Performance
VYGR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
VYGR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +383.2% | -122.8% | -88.8% |
| 3 y3 years | +305.3% | +46.7% | +131.7% |
| 5 y5 years | +242.1% | +46.7% | +131.7% |
VYGR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +284.7% | -110.2% | +55.7% | -88.8% | +120.6% |
| 5 y | 5-year | at high | +284.7% | -110.2% | +55.7% | -88.8% | +114.4% |
| alltime | all time | at high | +242.1% | -110.2% | +55.9% | -88.8% | +114.4% |
Voyager Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$12.65 M(-7.2%) | $14.13 M(-892.0%) |
| Jun 2024 | - | -$13.63 M(-9.0%) | -$1.78 M(-85.7%) |
| Mar 2024 | - | -$14.99 M(-127.1%) | -$12.49 M(-109.9%) |
| Dec 2023 | $126.45 M(-383.2%) | $55.40 M(-294.0%) | $126.45 M(+167.2%) |
| Sep 2023 | - | -$28.56 M(+17.3%) | $47.33 M(-48.4%) |
| Jun 2023 | - | -$24.34 M(-119.6%) | $91.67 M(-6.3%) |
| Mar 2023 | - | $123.96 M(-622.4%) | $97.85 M(-319.2%) |
| Dec 2022 | -$44.65 M(-34.8%) | -$23.73 M(-250.3%) | -$44.65 M(+225.1%) |
| Sep 2022 | - | $15.78 M(-186.9%) | -$13.73 M(-74.3%) |
| Jun 2022 | - | -$18.16 M(-2.0%) | -$53.44 M(-14.7%) |
| Mar 2022 | - | -$18.54 M(-358.0%) | -$62.68 M(-8.4%) |
| Dec 2021 | -$68.45 M(-319.4%) | $7.18 M(-130.0%) | -$68.45 M(-30.4%) |
| Sep 2021 | - | -$23.92 M(-12.7%) | -$98.38 M(-983.7%) |
| Jun 2021 | - | -$27.40 M(+12.7%) | $11.13 M(-63.5%) |
| Mar 2021 | - | -$24.32 M(+6.9%) | $30.48 M(-2.3%) |
| Dec 2020 | $31.20 M(-163.8%) | -$22.74 M(-126.6%) | $31.20 M(-23.8%) |
| Sep 2020 | - | $85.59 M(-1162.6%) | $40.93 M(-166.3%) |
| Jun 2020 | - | -$8.05 M(-65.9%) | -$61.75 M(+40.9%) |
| Mar 2020 | - | -$23.59 M(+81.3%) | -$43.83 M(-10.4%) |
| Dec 2019 | -$48.91 M | -$13.01 M(-23.9%) | -$48.91 M(-16.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$17.09 M(-273.3%) | -$58.49 M(-5.6%) |
| Jun 2019 | - | $9.87 M(-134.4%) | -$61.98 M(-36.1%) |
| Mar 2019 | - | -$28.68 M(+27.0%) | -$97.02 M(+9.0%) |
| Dec 2018 | -$88.98 M(+26.6%) | -$22.58 M(+9.7%) | -$88.98 M(+13.6%) |
| Sep 2018 | - | -$20.58 M(-18.3%) | -$78.31 M(-2.9%) |
| Jun 2018 | - | -$25.18 M(+22.0%) | -$80.65 M(+9.4%) |
| Mar 2018 | - | -$20.64 M(+73.2%) | -$73.70 M(+4.9%) |
| Dec 2017 | -$70.27 M(+72.7%) | -$11.91 M(-48.0%) | -$70.27 M(-2.5%) |
| Sep 2017 | - | -$22.92 M(+25.7%) | -$72.03 M(+21.4%) |
| Jun 2017 | - | -$18.23 M(+6.0%) | -$59.32 M(+17.3%) |
| Mar 2017 | - | -$17.20 M(+25.8%) | -$50.56 M(+24.3%) |
| Dec 2016 | -$40.69 M(+107.0%) | -$13.68 M(+34.0%) | -$40.69 M(+18.7%) |
| Sep 2016 | - | -$10.21 M(+7.9%) | -$34.28 M(+22.7%) |
| Jun 2016 | - | -$9.47 M(+29.1%) | -$27.93 M(+25.3%) |
| Mar 2016 | - | -$7.33 M(+0.8%) | -$22.29 M(+13.4%) |
| Dec 2015 | -$19.65 M(+38.6%) | -$7.28 M(+88.5%) | -$19.65 M(+17.2%) |
| Sep 2015 | - | -$3.86 M(+1.0%) | -$16.76 M(+1.6%) |
| Jun 2015 | - | -$3.82 M(-18.6%) | -$16.50 M(+30.2%) |
| Mar 2015 | - | -$4.70 M(+7.1%) | -$12.68 M(+58.9%) |
| Dec 2014 | -$14.18 M | -$4.38 M(+22.0%) | -$7.98 M(+122.0%) |
| Sep 2014 | - | -$3.59 M | -$3.59 M |
FAQ
- What is Voyager Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Voyager Therapeutics?
- What is Voyager Therapeutics annual EBITDA year-on-year change?
- What is Voyager Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Voyager Therapeutics?
- What is Voyager Therapeutics quarterly EBITDA year-on-year change?
- What is Voyager Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Voyager Therapeutics?
- What is Voyager Therapeutics TTM EBITDA year-on-year change?
What is Voyager Therapeutics annual EBITDA?
The current annual EBITDA of VYGR is $126.45 M
What is the all time high annual EBITDA for Voyager Therapeutics?
Voyager Therapeutics all-time high annual EBITDA is $126.45 M
What is Voyager Therapeutics annual EBITDA year-on-year change?
Over the past year, VYGR annual EBITDA has changed by +$171.10 M (+383.24%)
What is Voyager Therapeutics quarterly EBITDA?
The current quarterly EBITDA of VYGR is -$12.65 M
What is the all time high quarterly EBITDA for Voyager Therapeutics?
Voyager Therapeutics all-time high quarterly EBITDA is $123.96 M
What is Voyager Therapeutics quarterly EBITDA year-on-year change?
Over the past year, VYGR quarterly EBITDA has changed by -$68.05 M (-122.83%)
What is Voyager Therapeutics TTM EBITDA?
The current TTM EBITDA of VYGR is $14.13 M
What is the all time high TTM EBITDA for Voyager Therapeutics?
Voyager Therapeutics all-time high TTM EBITDA is $126.45 M
What is Voyager Therapeutics TTM EBITDA year-on-year change?
Over the past year, VYGR TTM EBITDA has changed by -$112.33 M (-88.83%)